Latest News

Pfizer plans a vaccine to target all coronaviruses


 

Ask the sibling of any celebrity and they’ll tell you they don’t get anywhere near the same attention. The same is true for coronaviruses – the one that causes COVID-19 has been in the spotlight for more than 2 years now, while the others at the moment circulate in relative obscurity.

With the knowledge that any of the other coronaviruses could pose a serious future threat, Pfizer and its partner BioNTech announced plans on June 29 to develop a vaccine that will work against SARS-CoV-2 (the virus that causes COVID-19) and the entire class, or family, of related coronaviruses.

Trials in people of this “pan-coronavirus” vaccine are scheduled to start this fall, Reuters reported. The aim of this universal vaccine is to lessen the threat from new variants before they emerge – to provide “durable variant protection.”

“I applaud the sentiment that is long overdue,” said Eric Topol, MD, when asked to comment. “It is crucial that we get ahead of the virus, and the best way is to develop pan-betacoronavirus vaccines that are variant-proof.”

“We had potential to get them into clinical trials many months ago, but this is the first sign it may happen,” said Dr. Topol, executive vice president of Scripps Research and editor-in-chief for Medscape, WebMD’s sister site for health care professionals.

SARS-CoV-2 is not the first troublemaker in the coronavirus family. SARS, a coronavirus that causes acute respiratory syndrome, emerged in late 2002. A decade later, officials sounded the alarm about the coronavirus behind Middle East respiratory syndrome (MERS).

The coronavirus family is large, but only seven coronavirus types can infect humans, the CDC reports. Most cause mild to moderate upper respiratory tract infections, although some people can get pneumonia or bronchiolitis.

Unless you’re a virologist, immunologist, or public health official, you may be unaware that coronaviruses are one of the causes of the common cold, for example.

A version of this article first appeared on WebMD.com.

Recommended Reading

FDA authorizes COVID vaccines in kids as young as 6 months
Journal of Clinical Outcomes Management
COVID-19 Pandemic stress affected ovulation, not menstruation
Journal of Clinical Outcomes Management
New saliva-based COVID-19 test provides rapid results
Journal of Clinical Outcomes Management
Children and COVID: Vaccines now available to all ages
Journal of Clinical Outcomes Management
Racial/ethnic disparities exacerbated maternal death rise during 2020 pandemic.
Journal of Clinical Outcomes Management
Children and COVID: Vaccination off to slow start for the newly eligible
Journal of Clinical Outcomes Management
COVID subvariants could cause ‘substantial’ summer cases
Journal of Clinical Outcomes Management
FDA panel backs adding Omicron component to COVID boosters
Journal of Clinical Outcomes Management
Acute hepatitis cases in children show declining trend; adenovirus, COVID-19 remain key leads
Journal of Clinical Outcomes Management
ACC/AHA issue clinical lexicon for complications of COVID-19
Journal of Clinical Outcomes Management